Inclusion Criteria: 

• Patients that are listed for lung transplantation and have:
  • PH defined as:
    • *Previous treatment or on treatment with PH medications;
    • Pulmonary artery pressures > 50% of systemic pressures.
  • Secondary PH (WHO Group 3) or diagnosis of primary PH (WHO Group 1).
  • Failing right ventricle function defined as:
    • A cardiac (CI) index < 2.2 L/min/m^2 despite continuous infusion of high dose inotropes defined as dobutamine > 10 ug/kg/min or equivalent for >15 minutes (120 minutes for milrinone) and/or administration of > 1 inotrope or vasopressor medication.
  • And have one of the following:
    • Central venous pressure (CVP) > 15 mm Hg;
    • Global RV dysfunction on echocardiography defined as one of the following:
      • A tricuspid annular plane systolic excursion score of < <14mm ii. an RV diameter at base > 42mm;
      • RV short-axis or midcavity diameter >35mm.
  • Age > 18 years old.
  • Signed informed consent.

Exclusion Criteria:

• INTERMACS 1 patients (Critical cardiogenic shock patient who is “crashing and burning”, has life-threatening hypotension and rapidly escalating inotropic or pressor support,with critical organ hypoperfusion often confirmed by worsening acidosis and lactate levels).
• End organ failure defined as: hepatic total bilirubin >5 mg/dL based on lab data within 24 hours prior to transseptal ECMO initiation; renal creatinine >4 mg/dLbased on lab data within the 24 hours prior to transseptal ECMO initiation.
• Evidence of acute neurologic injury.
• Active infection defined as two of the following WBC >12,500, positive blood culture, fever.
• RA thrombus.
• Thrombolysis within the previous 30 days or known existing coagulopathy such as thrombocytopenia or hemoglobin diseases such as sickle cell anemia or thalassemia.   

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/28/23. Questions regarding updates should be directed to the study team contact.